Zevra Therapeutics, Inc. Cash and Restricted Cash
Zevra Therapeutics, Inc. (ZVRA) had Cash and Restricted Cash of $2.89 million as of 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2018-11-09
- 2018-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.89M.
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.60M.
- 2018-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.85M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.97M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2018-09-30 | $2.89M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $17.60M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $9.85M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $11.97M 10-Q · filed 2018-11-09 |
| 2017-09-30 | $8.93M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $13.49M 10-Q · filed 2018-08-10 |
| 2017-03-31 | $12.88M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $17.86M 10-Q · filed 2018-11-09 |
| 2016-09-30 | $21.95M 10-Q · filed 2017-11-09 |
| 2016-06-30 | $28.61M 10-Q · filed 2017-08-10 |
| 2015-12-31 | $32.32M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |